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Introduction
Primary dysmenorrhea is defined as menstrual pain associ-
ated with ovulatory cycles and resulting from myometrial 
contraction in the absence of a pelvic disease that may cause 
abdominal pain. Traditionally, the activity of prostaglandin, a 
vasoconstrictor that causes ischemic pain in the uterus, is re-
garded as the cause of primary dysmenorrhea [1]. Although 
primary dysmenorrhea is common, it is frequently under-
diagnosed and under-treated [2]. Identification of the risk 
factors of primary dysmenorrhea may be useful for classifying 
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This study was aimed at identifying a correlation between polycystic ovarian morphology (PCOM) and the severity of 
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menstrual flow (OR, 1.85; 95% CI, 1.05–3.28; P=0.04) were found to be significant independent factors influencing 
pain.
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Our study shows that PCOM may have a correlation with the severity of primary dysmenorrhea. Since PCOM may play 
a role in the development of menstrual pain, patients with PCOM should be under active surveillance with resources 
for prompt pain management readily available. It may also be necessary to further investigate the molecular 
mechanisms of pain development in primary dysmenorrhea.
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women into groups that need active surveillance or prompt 
pain management.
Polycystic ovarian morphology (PCOM), one of the diagnos-
tic criteria for polycystic ovary syndrome (PCOS), is defined 
as the presence of >12 antral follicles 2–9 mm in diameter or 
an ovarian volume >10 mL [3]. The inclusion of PCOM in the 
diagnostic criteria for PCOS is controversial because the same 
morphology is found in 16–25% of asymptomatic women [4]. 
In a small study, the prevalence of PCOM was reported to be 
35–50% in healthy adolescent girls who were neither diag-
nosed with nor treated for PCOS 2–4 years after menarche 
[5-7]. The inclusion of PCOM to the PCOS spectrum is a topic 
of debate because ovulatory women with isolated PCOM 
frequently do not show clinical or biochemical evidence of 
androgen excess [8]. The clinical significance of PCOM is 
unclear. To date, PCOM is considered a pre-PCOS state, a 
normal morphological variant in adolescence, and a possible 
complication in high responders to controlled ovarian hyper-
stimulation [9]. 
The purpose of our study was to identify factors that may 
have a correlation with the severity of primary dysmenor-
rhea, and to investigate the relationship between PCOM and 
primary dysmenorrhea.
Materials and methods
1. Study population
A comparative study was conducted using a retrospective 
chart review of a total of 592 young, postmenarcheal Korean 
women aged <30 years old, who visited Severance Hospital, 
Yonsei University College of Medicine, between March 2008 
and March 2015 with dysmenorrhea as their chief complaint. 
After initial evaluation, 231 women were excluded for other 
possible causes of dysmenorrhea (Fig. 1). The initial evalua-
tion included history taking, pelvic examination, and imaging 
studies with either pelvic sonography (Accuvix V20 Prestige, 
Medison Co., Seoul, Korea) or abdominopelvic computed 
tomography. On their initial visit and using questionnaires, 
the patients provided information on their menstrual history 
which included cycle regularity and duration, quantity of 
menstruation, pain onset, any predictable patterns such as 
pain development timing and duration, any accompanying 
symptoms such as back pain, vomiting, diarrhea, or inter-
menstrual bleeding. Patients diagnosed with pelvic masses 
such as myoma and adnexal cyst, endometrial pathologies 
like polyp or submucosal myoma, endometriosis, and adeno-
myosis on imaging and patients with suspected symptoms 
of pelvic pathology were excluded from the analysis. Patients 
who, in the 3 months prior to their hospital visit, had taken 
hormonal agents such as oral contraceptives or progestin 
were also excluded. Finally, a total of 361 women with pri-
mary dysmenorrhea were recruited for the study [10]. 
2. Variables and measurements
Baseline physical examinations included measurements of 
height (cm), weight (kg), and body mass index (BMI, kg/m2). 
The pain intensity of dysmenorrhea was quantified using a 
visual analog scale (VAS) with scores from 0 to 10. Severe 
dysmenorrhea was defined as a VAS score ≥6. Irregular 
menstruation was defined in traditional terms as a cycle in-
terval >35 days or <21 days. Menstrual flow was classified as 
scanty, moderate, or heavy and PCOM was defined accord-
ing to the Rotterdam criteria [3]. Sonography was performed 
according to menstrual cycle; in the early follicular phase 
for patients with regular periods or with a dominant follicle 
or corpus luteum on ultrasound scan, and regardless of the 
ovulation cycle for patients with irregular periods of over 
90 days or amenorrhea. In patients with sonographic evi-
dence of ovarian cyst, the criteria for PCOM was applied 
using the 2–9 mm antral follicle count only. Smoking status 
was regarded as positive for current smokers only. The medi-
cations administered for menstrual pain relief after consulta-
Fig. 1. Flow chart of the participant inclusion in the study.
Total 592 postmenarcheal women
<30 years old
361 women were included
Excluded:
Adnexal cyst 38
Endometriosis 77
Adenomyosis 46
Myoma 34
Congenital anomaly 5
Endometrial pathology 22
Hormonal agents use 14
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tion were classified as none (no medication use), nonsteroidal 
anti-inflammatory drugs, and combined oral contraceptives, 
and information on the use of pain relief medications of dif-
ferent groups was considered.
3. Statistical analyses
Data are presented as mean±standard deviation for continu-
ous variables and as numbers and percentages for categori-
cal variables. The baseline characteristics between the mild 
and severe dysmenorrhea groups were compared using a 
2-sample t-test for continuous variables and the χ2 test for 
categorical variables. Logistic regression analyses were per-
formed to identify factors that are associated with severe 
primary dysmenorrhea. Logistic models were built based on 
the model’s goodness-of-fit and the multicollinearity of the 
factors. Previously known factors for primary dysmenorrhea 
with a P-value <0.1 in the univariate analysis were included 
in the logistic model. Data were analyzed using IBM SPSS ver. 
23.0 (IBM Corp., Armonk, NY, USA). A P-value <0.05 was 
considered statistically significant.
Results
A total of 361 patients with primary dysmenorrhea were 
included in the analyses. Their baseline characteristics 
are shown in Table 1. The mean age of the patients was 
23.0±4.0 years, the mean menstrual cycle duration was 
34.4±23.7 days, and the mean pain intensity measured on the 
VAS scale was 6.7±0.1. The mean BMI was 20.7±3.0 kg/cm2, 
which was within the normal range. Of the 361 patients, 
155 (42.9%) reported having mild dysmenorrhea (VAS ≤5) 
and 206 (57.1%) reported having severe dysmenorrhea (VAS 
≥6). Pelvic ultrasound examination of a total of 54 women 
(15%) showed PCOM. Baseline characteristics such as BMI 
and menstrual cycle duration were similar between women 
with mild dysmenorrhea and those with severe dysmenor-
rhea (Table 2). However, the proportion of women who had 
irregular menstrual cycles was significantly higher in the 
severe dysmenorrhea group (P=0.03). Furthermore, women 
with severe pain reported heavier menstrual flow than those 
with mild pain (P=0.02). The proportion of women with 
PCOM was also significantly higher in the severe dysmenor-
rhea group than in the mild dysmenorrhea group (P=0.03). 
A statistically significant difference in medication use for 
pain relief was observed between the 2 groups, with a 
higher frequency of combined oral contraceptive use in the 
severe dysmenorrhea group than in the mild dysmenorrhea 
group (P=0.04). Table 3 shows the adjustment model for 
women with severe primary dysmenorrhea. After adjusting 
for weight, height, menstrual cycle duration, and menstrual 
flow, PCOM showed a significantly increased odds ratio (OR) 
for severe dysmenorrhea (VAS score ≥6; OR, 2.26; 95% con-
fidence interval [CI], 1.05–4.97; P=0.04). Heavy menstrual 
flow was also associated with severe dysmenorrhea (OR, 1.85; 
95% CI, 1.05–3.28; P=0.04).
Discussion
In this study, we investigated the factors associated with 
severe pain in patients with primary dysmenorrhea. Of fore-
Table 1. Baseline characteristics of patients with primary dysmen-
orrhea
Variables Values
Age (yr) 23.0±4.0
Weight (kg) 54.1±8.4
Height (cm) 161.7±5.3
Body mass index (kg/cm2) 20.7±3.0
Menstrual cycle duration (day) 34.4±23.7
Pain intensity (VAS) 6.7±0.1
Menstrual flow  
Scanty 24 (6.6)
Moderate 232 (64.3)
Heavy 86 (23.8)
Dysmenorrhea 
Mild (VAS ≤5) 155 (42.9)
Severe (VAS ≥6) 206 (57.1) 
PCOM 54 (15)
Current smoker 9 (3.2)
Pain medication
None 125 (34.6)
NSAID 102 (28.3)
COC 134 (37.1) 
Data are presented as mean±standard deviation for continuous vari-
ables and as number (%) for categorical variables. 
SD, standard deviation; VAS, visual analog scale; PCOM, polycystic 
ovarian morphology; NSAID, nonsteroidal anti-inflammatory drug; 
COC, combined oral contraceptive. 
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most importance was our aim to ascertain the clinical sig-
nificance of PCOM beyond its potential status as a pre-PCOS 
state. The results revealed that PCOM and heavy menstrual 
flow may be associated with severe primary dysmenorrhea in 
young Korean women.
Our study, like a previous one, showed that the factors 
associated with primary dysmenorrhea include a history of 
heavy menstrual flow and irregular menstrual cycles [11]. 
However, our study is the first to reveal a strong correlation 
between PCOM and primary dysmenorrhea. The clinical 
significance of PCOM remains unclear, especially in young 
women. Previous studies posited that PCOM is a pre-PCOS 
state [12] or a prognostic factor in endometrial cancer for 
patients treated with progestin [13]. Another study described 
the correlation between PCOM and endometriosis [14]; how-
ever, only a few other similar studies have been conducted.
It is thought that the pain of primary dysmenorrhea may 
be due to increased prostaglandin levels, which causes in-
creased myometrial and uterine blood vessel contractions, 
thereby producing a relative ischemic uterine state [15]. The 
Table 2. Comparison of the mild and severe dysmenorrhea groups
Variables Mild (n=155) Severe (n=206) P-value 
Age (yr) 23.1±4.1 22.9±4.0 0.55
Weight (kg) 53±7.8 54.9±8.8 0.05
Height (cm) 160.8±5.2 162.4±5.3 0.01
Body mass index (kg/cm2) 20.5±3.0 20.8±3.0 0.43
Menstrual cycle duration (day) 33.7±28.7 35.0±18.7 0.61
Irregular period 42 (27.5) 76 (38.8) 0.03
Menstrual flow 0.02
Scanty+moderate 121 (81.2) 135 (69.9)
Heavy 28 (18.8) 58 (30.1)
PCOM 16 (10.3) 38 (18.4) 0.03
Current smoker 6 (4.8) 3 (2) 0.18
Pain medication 0.04
None 61 (39.4) 64 (31.1)
NSAID 48 (31) 54 (26.2)
COC 46 (29.7) 88 (42.7)  
Data are presented as mean±standard deviation for continuous variables and as number (%) for categorical variables. P-values were obtained 
using analysis of variance and 2-sample t-test for continuous variables, and the chi-square test for categorical variables.
PCOM, polycystic ovarian morphology; NSAID, nonsteroidal anti-inflammatory drug; COC, combined oral contraceptive.
Table 3. Adjusted odds ratios of variables for severe primary dysmenorrhea 
Variables Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value 
Weight 1.03 (1.0–1.06) 0.05 1.02 (0.98–1.05) 0.38
Height 1.06 (1.01–1.11) 0.01 1.04 (0.99–1.10) 0.11
Menstrual flow 
Scanty+moderate 1 1
Heavy 1.86 (1.11–3.1) 0.02 1.85 (1.05–3.28) 0.04
PCOM 1.97 (1.05–3.67) 0.03 2.26 (1.05–4.97) 0.04
Menstrual cycle duration 1.0 (0.99–1.01) 0.62 1.0 (0.99–1.01) 0.72
P-values were obtained using simple and multiple logistic regression analyses. The analyses were adjusted for weight (kg), height (cm), men-
strual cycle duration (days), menstrual flow (reference: scanty+moderate), and PCOM (reference: no PCOM).
OR, odds ratio; CI, confidence interval; PCOM, polycystic ovarian morphology.
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pain of primary dysmenorrhea is also known to be associated 
with sensitization of pain fibers. Peripheral factors and cen-
tral factors, such as brain-derived neurotrophic factor, were 
suggested as key factors in the central sensitization of pain in 
women with primary dysmenorrhea [16]. One possible expla-
nation for the correlation between PCOM and primary dys-
menorrhea may be uterine endothelial dysfunction. Increased 
serum levels of asymmetric dimethylarginine (ADMA), which 
is established as a strong marker of endothelial dysfunction 
in atherosclerosis, has been reported in patients with primary 
dysmenorrhea [17]. Regarding pain, it has been posited that 
arginine metabolism is 1 of the key mechanisms of pain de-
velopment in patients with sickle cell disease, a hemoglobin-
opathy with pain as a disease hallmark. Arginine is thought 
to play a key role in multiple metabolic processes, particularly 
with its contribution to endothelial dysfunction and vessel 
occlusion in sickle cell disease [18]. The same ADMA study 
group later demonstrated a positive correlation between 
serum ADMA and serum anti-Mullerian hormone (AMH) in 
young women with primary dysmenorrhea. They suggested 
that ADMA, like AMH, may be used as an ovarian reserve 
marker [19]. However, it is unclear how serum ADMA and 
AMH are connected in the larger context of PCOM, except 
that they share the same bone morphogenetic protein path-
way for signal transduction. The correlation between PCOM 
and serum AMH is well known, even though the patients in 
a few of the studies only had PCOM but not PCOS [20]. 
The relationship between heavy menstruation and pain as 
an inflammatory response caused by increased prostaglandin 
synthesis is well established. The serum levels of prosta-
glandins, specifically prostaglandin E2 [21] or F2a [22], are 
higher in women with heavy menstrual bleeding (HMB) as 
shown by data compiled over 30 years. Nonsteroidal anti-
inflammatory drugs (NSAIDs) help reduce HMB by inhibiting 
cyclo-oxygenase, thereby reducing prostaglandin production 
[21,23]. Increased prostaglandin level is a common finding 
in dysmenorrhea and HMB. The strong correlation between 
heavy menstrual flow and severe dysmenorrhea shown by 
our study may be explained by increased prostaglandin level. 
Our study reports the unique finding that PCOM is strongly 
associated with the severity of pain in women with primary 
dysmenorrhea; however, its retrospective nature is a limita-
tion. It is possible that pain was caused by undiagnosed 
secondary causes such as endometriosis since we did not 
routinely perform diagnostic laparoscopy. Our study is also 
limited by the fact that primary dysmenorrhea is a clinical 
diagnosis made on the basis of menstrual symptoms and by 
excluding pelvic pathologies that may cause pain. 
In conclusion, PCOM and heavy menstrual flow may posi-
tively correlate with the severity of pain in young women 
with primary dysmenorrhea. Since PCOM may play a role 
in the development of menstrual pain, patients with PCOM 
should be under active surveillance with resources for prompt 
pain management readily available. It may also be necessary 
to further investigate the molecular mechanisms of pain de-
velopment in primary dysmenorrhea.
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